Objectives: Patients with bipolar disorder spend the most time in the depressed phase, and that phase is associated with the most morbidity and mortality. Treatment of bipolar depression lacks a test to determine who will respond to treatment. White matter disruptions have been found in bipolar disorder. Previous reports suggest that white matter disruptions may be associated with resistance to antidepressant medication, but this has never been investigated in a prospective study using a Food and Drug Administration (FDA)-approved medication.
The medications often take weeks to take effect, so the treatment course is often drawn out. The pathophysiology of the disorder remains largely unknown, 3 making it harder to develop new, more effective treatments.
Previous studies have identified disruptions in white matter tracts on magnetic resonance imaging (MRI) scans using diffusion tensor imaging (DTI) or magnetic transfer ratio sequences in bipolar patients when compared to healthy volunteers. [4] [5] [6] Greater rates of white matter hyperintensities (WMHs) on T2-weighted fluid-attenuated inversion recovery images, also indicative of disruptions in white matter tracts, have been reported in bipolar disorder. 7 The clinical significance of these white matter disruptions has not been fully elucidated.
Previous retrospective studies found that higher rates of WMHs in bipolar disorder were associated with poor clinical outcomes, indicating that white matter disruptions may characterize a particular subtype of bipolar depression that is more treatment resistant. 8, 9 These studies were naturalistic in design, however, so the subjects had had different courses of treatment. Other studies have reported an association between white matter disruptions and treatment outcome in geriatric major depressive disorder, 10, 11 providing further evidence that white matter disruptions may be important to clinical response to medications.
One previous prospective study was performed to identify whether DTI signal was associated with response to an acute antidepressant treatment course in bipolar disorder. 12 That study used an experimental treatment, however, that included sleep deprivation and light therapy. A significant association was found between more DTI disruptions and poorer response to the treatment. To our knowledge, there are no prospective studies of white matter disruptions on MRI and treatment response to an FDA-approved medication for bipolar depression. Here, we studied whether white matter integrity was associated with the antidepressant response to lurasidone, an atypical antipsychotic recently approved for the treatment of depression in bipolar disorder.
| METHODS

| Subject recruitment
Twenty patients with bipolar disorder (type I, type II or not otherwise specified [NOS]) who were currently in a major depressive episode, and scored ≥16 on the Quick Inventory of Depressive Symptomatology-Self Rated version (QIDS-SR), were recruited.
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Subjects were excluded if they had current psychosis, significant suicide risk, recent substance abuse (within the last 2 months) or substance dependence (within the last 6 months), contraindications to MRI imaging such as known metal in the body or claustrophobia, previous lack of response to lurasidone, onset of mood disorder after age 40 years or taking medications that precluded a trial of lurasidone.
One subject withdrew from the study before starting medication, and one was excluded from the analysis because of having remitted from their depression before starting medication. Data presented here are from the remaining 18 subjects. Patients were medication free for 8 weeks before MRI. Rating Scale (MADRS) each week. 14 A curve was fitted for each subject's MADRS values over the 8-week course using a previously published mathematical model that uses information on the slope and curvature of the treatment response. 15 The extrapolated values from those curves at the baseline timepoint and at the last MADRS measurement were used to quantify the response ( Figure S1 ).
| MRI acquisition
| Clinical treatment
| MRI data analysis and statistics
Voxelwise statistical analysis of fractional anisotropy (FA) data was carried out using Tract-Based Spatial Statistics (TBSS), 16 part of FMRIB Software Library (FSL). 17 First, DTI images were motion corrected using FSL's eddy correct module, then they were brain-extracted using Brain Extraction Tool, 18 then FA images were created by fitting a tensor model to the raw diffusion data using FMRIB Diffusion
Toolbox. All subjects' FA data were aligned into a common space using the nonlinear registration tool FNIRT, 19 which uses a b-spline representation of the registration warp field. 20 Next, a mean FA image was created and thinned to create a mean FA skeleton which represents the centers of all tracts common to the group. Each subject's aligned FA data were projected onto this skeleton and the resulting data were fed into voxelwise cross-subject statistics. Statistical analyses were carried out with FSL's randomize tool, 21 which was used to perform a regression analysis on the FA data using percent change in MADRS as a regressor while controlling for age and sex, using a threshold of P (cluster corrected) <.05. Corrections for multiple comparisons were performed with threshold-free cluster enhancement (TFCE). 17 The
Institutional Review Board of the New York State Psychiatric Institute approved the study and all participants gave written informed consent. All research procedures were in accordance with the Helsinki Declaration of 1975.
| RESULTS
| Demographic data
Eighteen subjects (11 men and seven women), mean age, mean ± standard deviation (SD) 33.4 ± 9.8 years. The majority (61%) met DSM-IV criteria for bipolar II disorder, two (11%) those for bipolar I disorder, and five (28%) those for bipolar disorder, not otherwise specified. Three (17%) were Hispanic, seven (39%) were of a minority race and 14 (78%) were either single or divorced. Most were employed full-time (61%) and had completed a mean of 15.4 ± 1.7 years of education. Mean age of onset of depressive illness was 16.6 ± 9.5 years.
Lifetime co-morbid anxiety disorders included social phobia (six patients; 33%), and panic disorder and post-traumatic stress disorder (PTSD) (each three patients; 17% 
| Clinical response
The mean dosage of lurasidone at week 8 was 43. 
| Imaging data
TBSS analysis of white matter tracts demonstrated significant positive correlations between better antidepressant response to lurasidone and greater FA in multiple regions of the skeleton, with age and sex included as covariates (Figure 2 
| DISCUSSION
These data suggest that greater white matter integrity is associated with better treatment response to an acute course of an FDA-approved medication for bipolar depression, lurasidone. The association is widespread throughout the frontal and parietal cortices, but did not involve the cerebellum.
White matter pathology has been reported previously in bipolar disorder when compared to healthy volunteers using a number of MRI imaging modalities. 4, 5, 7 The cause of these abnormalities is largely unknown. White matter disruptions can be vascular in etiology, and are associated with cardiovascular risk factors in the population in general. They also increase in prevalence with age. 22 Increased rates of white matter hyperintensities in bipolar disorder have been found to be present in the adolescent bipolar population without significant cardiovascular pathology, indicating that the white matter disruptions may not be wholly due to these risk factors. 23 Disruptions of white matter on MRI is not a bipolar disorder specific finding, as other psychiatric conditions including schizophrenia and major depressive 
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Taken together, it is likely that the findings reflect a neuropathologic process of unknown mechanism affecting white matter tracts in bipolar disorder.
Disruptions in white matter tracts have been associated with greater neurocognitive deficits in bipolar disorder. 28, 29 Patients with major depressive disorder (MDD) with a history of suicide attempts have also been found to have higher rates of WMHs than those without attempts, indicating that the white matter disruptions may play a role in suicidal behavior. 30, 31 The latter finding complements our data to suggest that subjects with white matter disruptions comprise a group with more clinical challenges and risks.
A previous meta-analysis of white matter disruptions in bipolar disorder found that the posterior cingulate cortex was the most reliably disrupted when compared to healthy volunteers. 4 Here, we found white matter disruptions in tracts near the posterior cingulate to be associated with poor clinical treatment response to lurasidone. A number of previous DTI studies focused on the disruptions of white matter in the frontal lobe in bipolar disorder and found differences compared with healthy volunteers, consistent with our results. 32, 33 Frontal lobe white matter deficits may explain a frontal-limbic deficit in bipolar disorder that has been delineated through task-based functional MRI studies. 34 Frontal lobe deficits are also consistent with a number of symptoms of bipolar disorder, including distractibility, involvement in activities with high potential for painful consequences, and less cognitive regulation of emotion. 35 Our results were not limited to the frontal region, however, so it is not possible to determine from our study whether the frontal lobe disruptions are essential to the disruption in the antidepressant response.
Lurasidone's antipsychotic mechanism is thought to operate through either its serotonin 2A receptor or dopamine D2 receptor antagonism. However, its antidepressant mechanism remains largely unknown. One previous report found that clozapine, also an atypical antipsychotic, increased white matter FA in the brain of subjects with schizophrenia. 36 Another pilot study found that increased myelin integrity was associated with treatment response to antipsychotic medications in schizophrenia. 37 However, not all studies have replicated this finding. 38 Therefore, more work is needed to determine if atypical antipsychotics, and lurasidone in particular, can reverse the white matter disruptions in bipolar disorder. Our data suggest that white matter disruptions impede response to treatment. The results are consistent with lurasidone acting through either a monoaminergic mechanism or a reparative mechanism that targets white matter tracts.
Our study has several limitations. There was no healthy volunteer group to compare to the bipolar subjects. Therefore, there is no way to test whether the white matter disruptions are in fact a pathophysiological effect, as has been reported in other studies. There was no placebo treatment or active comparator arm to the study, and the treatment was not masked to participants or raters. Therefore, there is no way to know if the association with treatment outcome is related to lurasidone specifically or clinical improvement in general. There were no post-treatment scans, so there is no way to determine if lurasidone changes the white matter integrity. The results are also limited by the sample size. A larger study with these control groups and post-treatment scans could address these limitations. Future studies may also focus on alternate treatments that could target the white matter pathology of the disorder. For example, lithium has demonstrated neuroprotective properties, and previous pilot studies have reported better response to lithium in patients with more white matter hyperintensities. 
